Rezolute Inc (RZLT)

NASDAQ
3.19
+0.12(+3.91%)
  • Volume:
    3,489
  • Day's Range:
    3.02 - 3.19
  • 52 wk Range:
    2.27 - 11.19

RZLT Overview

Prev. Close
3.07
Day's Range
3.02-3.19
Revenue
-
Open
3.02
52 wk Range
2.27-11.19
EPS
-3.08
Volume
3,489
Market Cap
106.12M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
61,450
P/E Ratio
-1.00
Beta
3.01
1-Year Change
-71.11%
Shares Outstanding
33,582,831
Next Earnings Date
Sep 14, 2022
What is your sentiment on Rezolute?
or
Market is currently closed. Voting is open during market hours.

Rezolute Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Rezolute Inc Company Profile

Rezolute Inc Company Profile

Employees
26

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell